SB12 Equivalent to Soliris in Phase 1 Trial

SB12 Equivalent to Soliris in Phase 1 Trial

314795

SB12 Equivalent to Soliris in Phase 1 Trial

Samsung Bioepis announced that its product SB12, a proposed biosimilar — a product that is highly similar, with no clinically meaningful differences, to an original patented product — to Soliris (eculizumab), showed equivalent properties with regards to the therapy’s safety, pharmacokinetics, and immune profile in a Phase 1 trial in healthy volunteers. Pharmacokinetics refers to the movement of the therapy into, through, and out of the body. Soliris is an approved treatment for atypical hemolytic…

You must be logged in to read/download the full post.